Ocugen, Inc. announced the appointment of Quan A. Vu to Chief Business Officer. Quan has quickly become a tremendous asset for Ocugen and his comprehensive healthcare and financial expertise is providing valuable insight toward reaching the corporate goals, said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. With Quan now overseeing both finance and business development, there will be a fully integrated approach to financial strategypursuing new partnerships and engaging with the investment community.

Mr. Vu joined Ocugen on February 1, 2023, and has been working closely across multiple, key corporate functionsunderstanding short- and long-term business and financial needs of the Company along with the potential of its differentiated scientific platforms. With his additional appointment as Chief Financial Officer, and aside from his management and oversight of the finance and accounting functions, Mr. Vu will partner closely with Dr. Musunuri to enhance the Companys forward-looking, value-additive financial initiatives by leveraging the Companys anticipated clinical milestone achievements to bolster fundamental shareholder composition, expand interactions with the investor community, and ensure reputable capital markets and equity research support. Before joining Ocugen, Mr. Vu was most recently Chief Operating Officer/Chief Business Officer for 180 Life Sciences. He began his career in healthcare investment banking at both Morgan Stanley and Goldman Sachs, and then held leadership roles of increasing responsibility at Opiant Pharmaceuticals, Impax Laboratories, Anthem, and Amgen.

Mr. Vu obtained his BA in Economics from UCLA, graduating summa cum laude with College Honors and Economics Departmental Honors. He is also a Certified Treasury Professional (inactive).